Sanofi India - Insulin Glargine NLEM Inclusion - A Short Term Pain: Nirmal Bang
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
We have revised our earnings estimates on Sanofi India Ltd. to account for the adverse impact of Insulin Glargine’s inclusion under National List of Essential Medicines 2021 and announced divestment of its Nutraceuticals portfolio to Universal Nutriscience Pvt. Ltd.
We have also raised our operating margins estimates based on the recent performance trends.
With Lantus coming in drug price control order, there is very little incremental risk of NLEM on the earnings.
Potential NLEM inclusion of Lantus has for long been an overhang on Sanofi India and with the event behind us, the uncertainty is over.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.